SML3704
MRE-269
≥98% (HPLC)
동의어(들):
2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-acetic acid, ACT-333679, MRE 269, {4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}acetic acid
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C25H29N3O3
CAS Number:
Molecular Weight:
419.52
MDL number:
UNSPSC 코드:
12352200
NACRES:
NA.77
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
색상
, White to light brown
solubility
DMSO: 2 mg/mL, clear (Warmed)
저장 온도
-10 to -25°C
SMILES string
N(C(C)C)(CCCCOCC(=O)O)c1nc(c(nc1)c3ccccc3)c2ccccc2
InChI
1S/C25H29N3O3/c1-19(2)28(15-9-10-16-31-18-23(29)30)22-17-26-24(20-11-5-3-6-12-20)25(27-22)21-13-7-4-8-14-21/h3-8,11-14,17,19H,9-10,15-16,18H2,1-2H3,(H,29,30)
InChI key
OJQMKCBWYCWFPU-UHFFFAOYSA-N
생화학적/생리학적 작용
MRE-269 (ACT-333679) is an active form of Selexipag (NS-304). MRE-269 is a potent and highly selective IP receptor agonist (selective PGI2 receptor agonist).
Potent and highly selective IP receptor agonist; selective PGI2 receptor agonist
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Hidekazu Maruyama et al.
Life sciences, 315, 121372-121372 (2023-01-08)
Upregulated p38MAPK signaling is implicated in the accelerated proliferation of pulmonary artery smooth muscle cells (PA-SMCs) and the pathogenesis of pulmonary artery remodeling observed in pulmonary arterial hypertension (PAH). Previously, we reported that after endothelin-1 (ET-1) pretreatment, bone morphogenetic protein
Samuel N Baldwin et al.
British journal of pharmacology, 179(7), 1338-1352 (2021-11-13)
Prostacyclin mimetics express potent vasoactive effects via prostanoid receptors that are not unequivocally defined, as to date no study has considered sex as a factor. The aim of this study was to determine the contribution of IP and EP3 prostanoid
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.